BUSINESS● LOWAug 12 · Aug 12, 2026, 5:58 PM
Protalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approval
Seeking Alpha Tech
Protalix aims for 15-20% market share for its drug Elfabrio by 2031, supported by recent European approval for a specific dosing regimen. This indicates the company's strategic growth projections for its pharmaceutical product.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS21m agoFifth Third expects 2.5%-3.5% Q4 net interest income growth as it targets $200M-$300M buybacksSeeking Alpha TechBUSINESS32m agoServisFirst outlines 5-7 bps quarterly margin expansion as it launches 2m-share repurchase planSeeking Alpha Tech